In this large cohort, heavy smoking in midlife was associated with a greater than 100% increase in risk of dementia, AD, and VaD more than 2 decades later. 5 key findings →
Participants: 5,367
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Among 2935 patients (50.4% women; mean age=72.2 years; 19.8% subjective cognitive impairment, 39.8% mild cognitive impairment, and 40.4% dementia), larger WMH volume within projection fibres (B=0.24, SE=0.10, p=0.013) was associated with greater apathy. 5 key findings →
Participants: 2,935
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
52/100
✓ Peer-reviewed
alzhub usefulness score 52 out of 100.
·
Nature Aging
·
2025-11-20
Cerebral small vessel disease (cSVD) is a leading cause of stroke and dementia with no specific treatment, of which molecular mechanisms remain poorly understood. 2 key findings →
Participants: 40,000
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
52/100
✓ Peer-reviewed
alzhub usefulness score 52 out of 100.
·
Diabetes Care
·
2025-10-27
Diabetes was not associated with brain atrophy cross-sectionally or longitudinally. 5 key findings →
Design: cross-sectional
Participants: 112
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Our aim is to examine the interplay between cerebral small vessel disease (CSVD) pathology, Alzheimer’s disease (AD) related amyloid-β (Aβ) clearance, and cognition in general population. 2 key findings →
Design: cross-sectional
Participants: 1,026
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
52/100
✓ Peer-reviewed
alzhub usefulness score 52 out of 100.
·
Age and Ageing
·
2025-08-21
This study included 3540 participants with RVC data and 489 with WMH data (median [IQR] age: 73.2 [71.4-76.3] and 72.5 [71.2-75.4] years; female: 52.9% and 47.6%) over a median follow-up of 7.4 [IQR 5.5-8.5] and 3.8 [IQR 2.9-5.3] years, respectively. 5 key findings →
Design: cross-sectional
Participants: 3,540
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
52/100
✓ Peer-reviewed
alzhub usefulness score 52 out of 100.
·
Age and Ageing
·
2025-08-29
Out of 462,327 eligible participants, those with constipation were associated with higher incidence of three outcome diseases (1415/20,263 [7.0%]) than those without (18,848/442,064 [4.3%]), with adjusted hazard ratio (HR) being 1.35 [1.27-1.42]. 5 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Hypertension, acute myocardial infarction, atrial fibrillation, diabetes, heart failure, ischemic heart disease, stroke, and arthritis additively accounted for 71.8% (95% confidence interval [CI]: 62.9%-79.1%) of ADRD incident cases based on LE-AAF. 5 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
52/100
✓ Peer-reviewed
alzhub usefulness score 52 out of 100.
·
Neurology
·
2014-08-06
Our results confirm that vitamin D deficiency is associated with a substantially increased risk of all-cause dementia and Alzheimer disease. 5 key findings →
Participants: 171
Evidence: low
Full summary, score breakdown and related studies →
Original source
52/100
✓ Peer-reviewed
alzhub usefulness score 52 out of 100.
·
Neurology
·
1996-01-01
We used the medical records linkage system for the population of Rochester, Minnesota, to identify persons in the community who had their first cerebral infarct without previous dementia. 2 key findings →
Participants: 971
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
52/100
✓ Peer-reviewed
alzhub usefulness score 52 out of 100.
·
Neurology
·
2004-03-01
The cognitive deficits in VaD and VCI are characterized by disturbance of frontal functions, with less verbal memory impairment. 2 key findings →
Participants: 170
Evidence: low
Full summary, score breakdown and related studies →
Original source
52/100
✓ Peer-reviewed
alzhub usefulness score 52 out of 100.
·
Neurology
·
2006-09-01
Metabolic syndrome is associated with Alzheimer disease in elderly subjects. 5 key findings →
Participants: 959
Evidence: low
Full summary, score breakdown and related studies →
Original source
Central auditory dysfunction is a precursor to AD. 2 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Some patients receiving oral anticoagulation therapy are more challenging to maintain within the therapeutic range than others. 2 key findings →
Participants: 124,619
Evidence: low
Full summary, score breakdown and related studies →
Original source
Our results suggest that genes associated with clinical neurological disease also have detectable effects on subclinical phenotypes. 5 key findings →
Participants: 705
Evidence: low
Full summary, score breakdown and related studies →
Original source
Increased SBP and low milk intake in midlife were associated with VaD detected 25 to 30 years later. 5 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
52/100
✓ Peer-reviewed
alzhub usefulness score 52 out of 100.
·
Stroke
·
1997-04-01
We found that 451 (92.8%) of the patients were testable, 239 (49.2%) of the patients were women, and the mean age was 71.2 years. 5 key findings →
Participants: 486
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
52/100
✓ Peer-reviewed
alzhub usefulness score 52 out of 100.
·
PloS one
·
2013-05-01
TBI is an independent significant risk factor of developing dementia even in the mild type. 3 key findings →
Participants: 28,551
Evidence: low
Full summary, score breakdown and related studies →
Original source
The aging population is increasing and, therefore, a higher prevalence of cardiac disease is emerging; including hypertension, coronary artery disease, atrial fibrillation and chronic heart failure. 1 key finding →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
52/100
✓ Peer-reviewed
alzhub usefulness score 52 out of 100.
·
Stroke
·
2015-01-08
These cross-sectional results suggest that cortical changes (regional-specific damage and network breakdown), mediated (in)directly by WMH (tract-specific damage) and other factors (eg, vascular risk factors), might lead to cognitive decline. 5 key findings →
Design: cross-sectional
Participants: 426
Evidence: low
Full summary, score breakdown and related studies →
Original source
Log-rank testing, adjusted for matching, showed a highly significant difference in stroke-free survival between the two groups (p<0.0001). 4 key findings →
Participants: 4,709
Evidence: low
Full summary, score breakdown and related studies →
Original source
A total of 124 participants with Alzheimer disease, cerebrovascular disease, or a mix Alzheimer's and cerebrovascular diseases and 55 controlparticipants underwent magnetic resonance imaging and neuropsychological testing. 5 key findings →
Participants: 124
Evidence: low
Full summary, score breakdown and related studies →
Original source
Alzheimer's disease (AD) is characterized by senile plaques and neurodegeneration although the neurotoxic mechanisms have not been completely elucidated. 3 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
White matter hyperintensity (WMH), indicative of cerebral small vessel disease, has emerged as a potential biomarker for cognitive decline in Alzheimer's disease (AD). 2 key findings →
Design: cross-sectional
Participants: 158
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Considerable data support the presence of both systemic and CNS inflammation in SVD and VCID. 3 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 27,380 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.